AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinib

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability